MOLOGNI LUCA

Villa, M., Malighetti, F., Villa, A., Cordani, N., Aroldi, A., Zambon, A., et al. (2026). Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. JOURNAL OF TRANSLATIONAL MEDICINE [10.1186/s12967-026-08420-7]. Dettaglio

Civettini, I., Malighetti, F., Villa, M., Crippa, V., Aroldi, A., Cavalca, F., et al. (2026). Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution. NEJM EVIDENCE, 5(6), 1-13 [10.1056/evidoa2500124]. Dettaglio

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio

Zapata Dongo, R., Poterico, J., Fontana, D., Mologni, L., Alvarez-Chacon, C., Rojas-Armas, J., et al. (2025). An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer. FRONTIERS IN PHARMACOLOGY, 16 [10.3389/fphar.2025.1605314]. Dettaglio